Bob Hariri

Dr. Bob Hariri is an accomplished surgeon, biomedical scientist, and serial entrepreneur in two technology sectors, biomedicine and aerospace. He is the chairman, founder, and chief executive officer of Celularity, Inc., one of the world's leading human cellular therapeutics companies. Dr. Hariri was the founder and CEO of Anthrogenesis Corporation, and after its acquisition by Celgene Corporation, served as CEO of Celgene Cellular Therapeutics. Dr. Hariri also co-founded the genomic-based health intelligence company, Human Longevity, Inc. Dr. Hariri pioneered the use of stem cells to treat a range of life-threatening human diseases, and continues today to make transformative contributions in the fields of immuno-oncology and cell therapeutics along with tissue engineering and functional regeneration. He is widely acknowledged for his discovery of pluripotent stem cells derived from the human placenta, and as a member of the team that discovered the physiological activities of tumor necrosis factor (TNF). He holds over 150 issued and pending patents for discoveries including placenta-derived stem cells, which Nature recognized as one of the ten most important patent estates in the field. He has authored over 150 published chapters, articles, and abstracts. Dr. Hariri completed his undergraduate training at Columbia University School of Engineering and Applied Sciences and Columbia College. He received his M.D. and Ph.D. degrees from Cornell University, where he was the recipient of both the Julian R. Rachele Award and the Doctoral Dissertation Award. He completed his surgical training at The New York Hospital-Cornell Medical Center.


01.30 - 01.50
DP World Hall
Celularity is a development-stage company delivering allogeneic therapies from engineered cells and cell products derived from the human placenta, for applications in cancer immunology, and autoimmune and inflammatory diseases. These proprietary, placenta-derived allogeneic cells are immuno-compatible “universal donor” cells, from which Celularity is developing an on-demand suite of allogeneic cell therapy products. These products include novel placenta-derived natural killer (PNK) & cryopreserved PNK (CYNK) as well as genetically modified PNK/CYNK constructs. Celularity’s was the first allogeneic cancer immunotherapy used in human patients (August 2016) and has demonstrated competing results in early-stage human clinical trials in multiple myeloma and AML.